Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma
ALPI
1 other identifier
interventional
80
1 country
1
Brief Summary
Glaucoma is the leading cause of irreversible blindness worldwide. With ageing of the population, glaucoma morbidity will rise, causing increased health care costs and economic burden for a condition in which visual loss, once established, cannot be reversed. In contrast to western countries, primary angle closure glaucoma (PACG) is a major form of glaucoma in Asia. In a recent population based survey in Singapore, the prevalence of glaucoma was 3.2% in the Chinese population over 40. Glaucoma was the leading cause of blindness, with PACG the most visually destructive form of the disease. Laser iridotomy is the current first line treatment for PACG. It acts by relieving pupil block, which in turn may reduce intraocular pressure (IOP) and prevent progression of glaucoma. However recent data indicate that iridotomy is not successful in controlling IOP in the long term, and the majority of cases develop a clinically significant rise in IOP requiring medical therapy or surgery. Argon laser peripheral iridoplasty (ALPI) offers a new therapeutic option for PACG. The procedure consists of placing contraction burns in the iris periphery which results in contraction of the iris stroma and opening of the angle. The proposed study is a 2-centre randomized controlled trial to determine whether ALPI is an effective and safe treatment in the management of PACG. 210 patients with PACG and high IOP (\>21 mmHg) following laser iridotomy will be randomized to receive ALPI or medical treatment to achieve IOP control. Subjects will be followed up for 12 months and the outcome criteria will be the rate of medical treatment and surgery in each group, and the angle width and configuration. This will be the first RCT worldwide to address the role of ALPI in PACG. The study findings will have great relevance for the prevention of glaucoma blindness in the elderly.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 18, 2009
CompletedFirst Posted
Study publicly available on registry
September 21, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedJune 17, 2011
November 1, 2009
4 years
September 18, 2009
June 16, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary outcome will be the number of patients in each group on medical treatment or having had surgical treatment at 12 months. The mean number of medications required to control IOP in each group will also be analyzed.
one year
Secondary Outcomes (1)
The secondary outcome will be the change in angle width and configuration as measured by gonioscopic examination, ultrasound biomicroscopy (UBM) and anterior segment OCT assessment at 1 month, 6 months and 12 months following entry into the study.
one year
Study Arms (2)
Iridoplasty
ACTIVE COMPARATORControl (Medication)
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Persistent narrow angle in the presence of a patent laser peripheral iridotomy. A narrow angle is defined as an angle width of 0-10º in 2 or more quadrants of either eye or where the pigmented trabecular meshwork is not visible in for 2 or more quadrants on gonioscopic examination
- Intraocular pressure \> 21mmHg on or off topical medication at least four weeks following laser iridotomy
- Intra ocular pressure \> 21 mm Hg after wash out regimen as described below for patients who are already on one medication and Iridotomy has been done at least 4 weeks ago.
- Informed Consent
- Age more than 21 years
You may not qualify if:
- Age less than 21 years
- Secondary causes of angle closure like subluxed lens, uveitis, trauma and neovascular glaucoma
- Presence of advanced sight-threatening glaucoma defined as vertical cup-disc ratio \> 0.9
- Presence of significant synechial angle closure with \> 6 clock hours of peripheral anterior synechiae (defined as abnormal adhesions of the iris to the angle that are at least half a clock hour in width and be at least to the anterior trabecular meshwork or higher on indentation gonioscopy)
- Cataract that is deemed significant enough to require surgery during the course of the trial or that makes field testing or optic disc imaging not technically possible- visual acuity less than 20/40 due to any type of cataract.
- Corneal endothelial cell count less than 1000 cells/mm2
- Corneal abnormalities or infection
- Previous intraocular surgery
- Use of contact lens
- Chronic use of topical or systemic steroids
- Participation in another therapeutic drug study within the last 30 days
- Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, respiratory disease, or cancer and life expectancy less than one year.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Singapore National Eye Centre
Singapore, 168751, Singapore
Related Publications (1)
Narayanaswamy A, Baskaran M, Aung T. Reply. Ophthalmology. 2016 Aug;123(8):e50-e51. doi: 10.1016/j.ophtha.2016.01.051. No abstract available.
PMID: 27450828DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
September 18, 2009
First Posted
September 21, 2009
Study Start
September 1, 2007
Primary Completion
September 1, 2011
Last Updated
June 17, 2011
Record last verified: 2009-11